A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years-Reference-Cited by-同舟云学术

A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years

Published:2020-06-18 Issue:1 Volume:20 Page:
ISSN:1471-2334
Container-title:BMC Infectious Diseases
language:en
Short-container-title:BMC Infect Dis

Author:

Borja-Tabora Charissa Fay Corazon,Peyrani Paula^ORCID,Webber Chris,Van der Wielen Marie,Cheuvart Brigitte,De Schrevel Nathalie,Bianco Veronique,Aris Emmanuel,Cutler Mark,Li Ping,Perez John L.

Funder

Pfizer Inc

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases

Link

http://link.springer.com/content/pdf/10.1186/s12879-020-05104-5.pdf

Reference23 articles.

1. McCarthy PC, Sharyan A, Sheikhi Moghaddam L. Meningococcal vaccines: current status and emerging strategies. Vaccines. 2018;6(1). https://doi.org/10.3390/vaccines6010012 .

2. Vuocolo S, Balmer P, Gruber WC, Jansen KU, Anderson AS, Perez JL, York LJ. Vaccination strategies for the prevention of meningococcal disease. Hum Vaccin Immunother. 2018;14(5):1203–15.

3. Meningococcal meningitis. World Health Organization. 2018. https://www.who.int/en/news-room/fact-sheets/detail/meningococcal-meningitis. Accessed 22 May 2020.

4. Purmohamad A, Abasi E, Azimi T, Hosseini S, Safari H, Nasiri MJ, Imani Fooladi AA. Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: a systematic review and meta-analysis. Microb Pathog. 2019;134:103571.

5. Meningococcal disease. In: Centers for disease control and prevention. epidemiology and prevention of vaccine-preventable diseases, 13th Edition. 2015. p 231–245.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody persistence and revaccination recommendations of MenACWY-TT: a review of clinical studies assessing antibody persistence up to 10 years after vaccination;Expert Review of Vaccines;2024-06-07

2. Assessing the Role of Infant and Toddler MenACWY Immunisation in the UK: Does the Adolescent MenACWY Programme Provide Sufficient Protection?;Vaccines;2023-05-04

3. A phase 3, randomized, controlled, open-label study to evaluate the persistence up to 5 years of 1 or 2 doses of meningococcal conjugate vaccine MenACWY-TT given with or without 13-valent pneumococcal conjugate vaccine in 12–14-month-old children;Vaccine;2023-01

4. Clinical trial and postmarketing safety experience with MenACWY-TT, a meningococcal group A, C, W, and Y tetanus conjugate vaccine;Vaccine;2022-11

5. Invasive meningococcal disease in Chile seven years after ACWY conjugate vaccine introduction;Vaccine;2022-01